Prevalence and longitudinal effects on mortality associated with spectrum of alcohol intake in steatotic liver disease: a United States population study.

BACKGROUND

The recently introduced set of terminologies defining categories of steatotic liver disease (SLD) includes metabolic dysfunction-associated SLD (MASLD), alcohol-associated liver disease (ALD), and metabolic dysfunction associated steatotic liver disease and increased alcohol intake (MetALD). The present retrospective cohort study examines clinical characteristics, prevalence, and mortality risk across alcoholic intake spectrum in SLD individuals.

METHODS

Data between 1999 to 2018 were extracted from National Health and Nutrition Examination Survey registries and analysed. Population baseline characteristics were evaluated across classifications of SLD. SLD was confirmed using either fatty liver index (FLI) or United States FLI (US-FLI). Multivariate analyses were used to study mortality-related outcomes.

RESULTS

The 20,510 individuals with SLD included were classified into MASLD predominant (69.00%), MetALD (18.77%), and ALD predominant (12.23%) groups. Temporal analysis revealed significant decreases in MASLD prevalence in the SLD population from 1999-2018 in general [average annual percentage change (AAPC) -4.802%, P=0.001], as well as in females, Mexican Americans, and Non-Hispanic Blacks. MetALD prevalence in the SLD population increased from 1999-2018 in general (AAPC +1.635%, P<0.001), and in males, females, Mexican Americans, Non-Hispanic Blacks and other ethnicities. No significant change in ALD prevalence was found. Compared to MASLD predominant individuals, ALD predominant individuals had higher risks of all-cause [hazard ratio (HR): 1.189, 95% confidence interval (CI): 1.026 to 1.378, P=0.02] and cancer-related mortality (subdistribution HR: 1.277, 95% CI: 1.032 to 1.579, P=0.02). No significant difference was observed for all-cause, cancer-related, or cardiovascular disease (CVD)-related mortality in MetALD and CVD-related mortality in ALD predominant individuals, relative to MASLD predominant individuals.

CONCLUSIONS

ALD predominant patients have higher all-cause and cancer-related mortality risks than MASLD predominant patients but not CVD-related mortality. SLD is highly heterogeneous in clinical characteristics, prevalence, and mortality risks which healthcare professionals must account for to avert adverse health outcomes.